DRug Integrative discoVEry of Molecular RadioTherapy: A premium “nuclear medicine” solution in Oncology
DRIVE-MRT is part of our continuous improvement in the integrated drug discovery support. Oncodesign and its strategic partners Covalab, CheMatech, and ABX-CRO are applying their expertise in the rationalization, design, and optimization of targeted radiopharmaceutical agents.
We can support your preclinical proof of concept, dosimetry, and the clinical development in specific cancers.
This offer gives access to a comprehensive continuum of technological platforms together with our strategic partners’ complementary expertise.
The ABX-CRO, CheMatech, Covalab and Oncodesign joint value proposition for a DRIVE-MRT offer encompassing from hit finding, lead optimization to the preclinical candidate drug generation, IND and clinical development of radiopharmaceuticals can be built and strengthened upon the complementary technologies and expertise of all parties.
Do you have a process to bioconjugate and radiolabel your compound?
When linked with a chelating agent, do the compound have the same affinity, target engagement, in vivo biodistribution?
The key objective of the Lead optimization phase is to define the best strategy of bioconjugation, selection of linker (PEG, BSA binder…), and radiolabeling in order to select an optimal bioconjugated compound (and possibly 2-3 back-up compounds) with improved binding demonstrating a robust selectivity and in vivo biodistribution.
To undergo regulatory IND-enabling studies, critical questions require to be addressed. What is the proof of concept and the pharmaceutical developability behind new target or biomarker? What is the therapeutic preclinical efficacy of this new molecule?
We design and implement preclinical studies to demonstrate the translational validity of novel pharmaceuticals as imaging or therapeutic agents using in vitro, ex vivo and in vivo assays in the appropriate models.
How to define the regulatory preclinical package for a radiopharmaceutical for diagnostic or therapeutic application?
We can provide you with a cGMP service to produce starting materials and intermediates. CheMatech conducts in-house cGMP manufacturing of chelating agents from grams to kilo. ABX-CRO will support your Radiopharmaceutical Development and dosimetry. Oncodesign can manage the toxicity studies and perform the GLP bioanalysis.